Video Experimental Relacionado
Updated: Sep 10, 2025
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
17.4K
Reducción de la duración de la anticoagulación en niños después de una trombosis venosa profunda provocada
Benjamin Feijóo1, Roxanne Radi2, Corey Lyon1
1From the University of Colorado Family Medicine Residency, Aurora, CO (BF, RR, CL).
Journal of the American Board of Family Medicine : JABFM
|August 25, 2025
Resumen
En pacientes jóvenes con trombosis venosa profunda provocada (TVP), un tratamiento anticoagulante de 6 semanas es tan eficaz como un régimen de 3 meses. Este hallazgo apoya la reducción de la duración del tratamiento en casos de TVP pediátrica y en adolescentes.
Área de la Ciencia:
- Hematología
- Trombosis pediátrica
- Medicina vascular
Sus antecedentes:
- La trombosis venosa profunda (TVP) es una afección vascular significativa.
- La duración óptima de la anticoagulación en las poblaciones pediátricas y adolescentes sigue siendo objeto de investigación.
- La TVP provocada en individuos más jóvenes presenta desafíos de manejo únicos.
Objetivo del estudio:
- Comparar la eficacia y la seguridad de 6 semanas frente a 3 meses de anticoagulación en pacientes menores de 21 años con TVP provocada.
- Para determinar la no inferioridad de la duración más corta de la anticoagulación.
- Informar las directrices clínicas para el manejo de la TVP pediátrica.
Principales métodos:
- Diseño del estudio prospectivo.
- Inclusión de pacientes menores de 21 años con un primer episodio de TVP provocada.
- Randomización a 6 semanas o 3 meses de tratamiento con anticoagulantes.
- Seguimiento de tromboembolismo venoso recurrente y eventos hemorrágicos.
Principales resultados:
- Se encontró que la anticoagulación durante 6 semanas no era inferior a 3 meses en la prevención de la TVP recurrente.
- No hubo diferencias significativas en los acontecimientos hemorrágicos mayores entre las dos duraciones de tratamiento.
- El estudio alcanzó su objetivo primario de no inferioridad.
Conclusiones:
- Un curso de anticoagulación de 6 semanas es una alternativa segura y efectiva a 3 meses para la TVP provocada en pacientes menores de 21 años.
- Una duración más corta de la anticoagulación puede reducir la carga del tratamiento y las posibles complicaciones.
- Los hallazgos apoyan estrategias de tratamiento individualizadas basadas en factores provocadores y la edad del paciente.
Videos de Conceptos Relacionados
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893
01:30Venous Thrombosis IV: Nursing Management
23
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
23
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
34
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
34
01:30Venous Thrombosis I: Introduction
40
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
40